Chronic Diseases Congress Market Analysis and Reports | Japan Conference Series

Market Analysis - Chronic Diseases Congress 2020

The world now has to come to terms with a worrying increase in the prevalence of chronic diseases. Responsible for more than 63% of all deaths, they are by far the world's biggest killers. If nothing is done to curb this trend, the number of deaths from chronic diseases could rise by 17% over the next 10 years.
 
According to the WHO, millions of lives could be saved and healthcare expenditure considerably reduced by national campaigns.
 
Campaigns, such as
 
Initiatives designed to reduce exposure to risk factors, such as tobacco smoke, alcohol consumption, sedentary lifestyles, and poor diet
Consistent measures to improve care, increase screening and provide early-stage treatment of chronic diseases
Why in Japan?
 
The chronic disease management system is developing quickly. In 2006, the Japan Chronic Disease Self-Management Association (J-CDSMA) was approved by the Japanese government as a non-profit organization. This organization was formed for the purpose of incorporating the principles of the Chronic Disease Self-Management Program (CDSMP), developed at Stanford University, into the Japanese healthcare system. Although disease management programs faced opposition by the Japan Medical Association because of concerns with quality issues early on, chronic disease management has, to a certain extent, been integrated into the Japanese healthcare system. In 2008, the Japanese government created the Tokugeti-Kenshin system, a program to prevent lifestyle diseases by allowing citizens between the ages of 40 to 74 to receive a free annual health checkup. In the private sector, DPP Health Partners (Hiroshima, Japan) was established in 2010 as the first disease management company in Japan, and a number of other disease management programs have followed.
 
Organizations such as the J-CDSMA do not provide disease management services, but they create a support network for chronic disease management in Japan. The J-CDSMA offers workshops that assist chronically ill patients on communicating with others, creating individualized “action plans,” and empathizing with each other. Other organizations that comprise this support network include the Disease Management Association of Japan and the Japan Society for Health Support Sciences. With their contribution, the awareness of major chronic diseases is approximately 70% in Japan, but other chronic conditions such as chronic obstructive pulmonary disease (COPD) still have low awareness.
 
Global Market:
 
Chronic diseases and conditions such as heart disease, stroke, cancer, type 2 diabetes, obesity, and arthritis—are among the most common, costly, and preventable of all health problems.
 
As of 2012, about half of all adults—117 million people—had one or more chronic health conditions. One in four adults had two or more chronic health conditions. Seven of the top 10 causes of death in 2014 were chronic diseases. Two of these chronic diseases—heart disease and cancer—together accounted for nearly 46% of all deaths. Cardiovascular Diseases Therapeutics is estimated to increase at a CAGR of 4.1% globally. The top eight markets to grow are of Germany, France, Italy, Spain, Japan, UK and USA. Obesity is a serious health concern. During 2011–2014, more than one-third of adults (36%), or about 84 million people, were obese (defined as body mass index [BMI] ≥30 kg/m2). About one in six youths (17%) aged 2 to 19 years was obese (BMI ≥95th percentile). Arthritis is the most common cause of disability.4 Of the 54 million adults with doctor-diagnosed arthritis, more than 23 million say they have trouble with their usual activities because of arthritis. Diabetes is the leading cause of kidney failure, lower-limb amputations other than those caused by injury, and new cases of blindness among adults. Europe Autoimmune disease therapeutics market is projected to create up to USD 4.58 billion at a CAGR of 1.6% by 2020 control and prevent diseases. However, the global autoimmune diseases treatment market is estimated to reach $15.97 billion by 2022 at CAGR of 3.80%